RS63359B1 - Heterociklična jedinjenja kao inhibitori pi3k-gama - Google Patents
Heterociklična jedinjenja kao inhibitori pi3k-gamaInfo
- Publication number
- RS63359B1 RS63359B1 RS20220521A RSP20220521A RS63359B1 RS 63359 B1 RS63359 B1 RS 63359B1 RS 20220521 A RS20220521 A RS 20220521A RS P20220521 A RSP20220521 A RS P20220521A RS 63359 B1 RS63359 B1 RS 63359B1
- Authority
- RS
- Serbia
- Prior art keywords
- pi3k
- heterocyclic compounds
- gamma inhibitors
- gamma
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252050P | 2015-11-06 | 2015-11-06 | |
PCT/US2016/060468 WO2017079519A1 (en) | 2015-11-06 | 2016-11-04 | Heterocyclic compounds as pi3k-gamma inhibitors |
EP16805238.9A EP3371190B1 (en) | 2015-11-06 | 2016-11-04 | Heterocyclic compounds as pi3k-gamma inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RS63359B1 true RS63359B1 (sr) | 2022-07-29 |
Family
ID=57460598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20220521A RS63359B1 (sr) | 2015-11-06 | 2016-11-04 | Heterociklična jedinjenja kao inhibitori pi3k-gama |
Country Status (17)
Country | Link |
---|---|
US (4) | US10065963B2 (sr) |
EP (2) | EP4086259A1 (sr) |
JP (1) | JP6854817B2 (sr) |
AR (1) | AR106595A1 (sr) |
DK (1) | DK3371190T3 (sr) |
ES (1) | ES2915550T3 (sr) |
HR (1) | HRP20220599T1 (sr) |
HU (1) | HUE059324T2 (sr) |
LT (1) | LT3371190T (sr) |
MA (1) | MA43169B1 (sr) |
MD (1) | MD3371190T2 (sr) |
PL (1) | PL3371190T3 (sr) |
PT (1) | PT3371190T (sr) |
RS (1) | RS63359B1 (sr) |
SI (1) | SI3371190T1 (sr) |
TW (2) | TWI824309B (sr) |
WO (1) | WO2017079519A1 (sr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3215510B1 (en) | 2014-11-06 | 2023-06-07 | Bial-R&D Investments, S.A. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
DK3215511T3 (da) | 2014-11-06 | 2024-05-13 | Bial R&D Invest S A | Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
EP4086259A1 (en) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
AU2017222958B2 (en) * | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
CA3022670A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
CA3084589A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
WO2019120212A1 (zh) * | 2017-12-19 | 2019-06-27 | 基石药业(苏州)有限公司 | Ido抑制剂 |
HUE066111T2 (hu) | 2018-09-05 | 2024-07-28 | Incyte Corp | Foszfoinozitid-3-kináz (PI3K) gátló kristályos formái |
AU2020247990A1 (en) | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
WO2020208222A1 (en) * | 2019-04-11 | 2020-10-15 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as malt1 inhibitors |
WO2020247504A1 (en) * | 2019-06-06 | 2020-12-10 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
CA3160637A1 (en) | 2019-11-08 | 2021-05-14 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
CN116348453A (zh) * | 2021-04-25 | 2023-06-27 | 烨辉医药科技(上海)有限公司 | 杂芳族甲酰胺化合物及其用途 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
EP1436291B1 (en) | 2001-09-19 | 2009-01-14 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
WO2004078943A2 (en) | 2003-03-04 | 2004-09-16 | California Institute Of Technology | Alternative heterocycles for dna recognition |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2007501189A (ja) | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ,インコーポレイテッド | フラビウイルス科に対する二環式イミダゾール誘導体 |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
EP1885352A2 (en) | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
WO2007019416A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
KR101324737B1 (ko) | 2005-12-13 | 2013-11-05 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로[2,3-b]피리딘 및 피롤로[2,3-b]피리미딘 |
JP2009541268A (ja) | 2006-06-22 | 2009-11-26 | ビオヴィトルム・アクチボラゲット(プブリクト) | Mnkキナーゼ阻害剤としてのピリジンおよびピラジン誘導体 |
WO2009005551A2 (en) | 2007-03-27 | 2009-01-08 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
CA2709883A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
CA2712071A1 (en) | 2008-01-15 | 2009-10-08 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
WO2009133127A1 (en) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
EP2358202B1 (en) | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
TW201028399A (en) | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010135014A1 (en) | 2009-02-27 | 2010-11-25 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
TWI490219B (zh) | 2009-06-29 | 2015-07-01 | Incyte Corp | 作為pi3k抑制劑之嘧啶酮 |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
TW201130842A (en) | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
NO3050882T3 (sr) | 2010-03-10 | 2018-06-30 | ||
JP2013523766A (ja) | 2010-03-31 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのイミダゾリル‐イミダゾール |
CA2796311A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | Fused derivatives as pi3k.delta. inhibitors |
CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
EP2627650A2 (en) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
KR20140091462A (ko) | 2010-10-13 | 2014-07-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 헤테로아릴 및 그의 용도 |
UA113156C2 (xx) | 2010-11-19 | 2016-12-26 | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
JP5824517B2 (ja) | 2010-11-30 | 2015-11-25 | 武田薬品工業株式会社 | 二環性化合物 |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
KR20140093610A (ko) * | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
JP6463631B2 (ja) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Gpr−119のモジュレータとしての新規化合物 |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
EP2751109B1 (en) | 2011-09-02 | 2016-11-30 | Incyte Holdings Corporation | Heterocyclylamines as pi3k inhibitors |
JP5854390B2 (ja) | 2012-03-01 | 2016-02-09 | 学校法人兵庫医科大学 | 新規ベンズイミダゾール誘導体及びその用途 |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2013180193A1 (ja) | 2012-05-31 | 2013-12-05 | 住友化学株式会社 | 縮合複素環化合物 |
CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
MX2015005428A (es) | 2012-11-01 | 2015-07-21 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak). |
TW202214254A (zh) | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
WO2014182954A1 (en) | 2013-05-08 | 2014-11-13 | Colorado Seminary, Which Owns And Operates The University Of Denver | Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase |
CA2911536C (en) | 2013-05-17 | 2021-07-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
MX2016000654A (es) | 2013-07-17 | 2016-05-26 | Otsuka Pharma Co Ltd | Compuestos de cianotriazol. |
US9751888B2 (en) * | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
EP2930048A1 (en) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Head up display projecting visual information onto a screen |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
JP6660060B2 (ja) | 2014-09-16 | 2020-03-04 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
EP4086259A1 (en) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
-
2016
- 2016-11-04 EP EP22162035.4A patent/EP4086259A1/en not_active Withdrawn
- 2016-11-04 US US15/343,375 patent/US10065963B2/en active Active
- 2016-11-04 TW TW110136698A patent/TWI824309B/zh active
- 2016-11-04 DK DK16805238.9T patent/DK3371190T3/da active
- 2016-11-04 MA MA43169A patent/MA43169B1/fr unknown
- 2016-11-04 PL PL16805238.9T patent/PL3371190T3/pl unknown
- 2016-11-04 MD MDE20180887T patent/MD3371190T2/ro unknown
- 2016-11-04 LT LTEPPCT/US2016/060468T patent/LT3371190T/lt unknown
- 2016-11-04 EP EP16805238.9A patent/EP3371190B1/en active Active
- 2016-11-04 ES ES16805238T patent/ES2915550T3/es active Active
- 2016-11-04 SI SI201631549T patent/SI3371190T1/sl unknown
- 2016-11-04 HU HUE16805238A patent/HUE059324T2/hu unknown
- 2016-11-04 PT PT168052389T patent/PT3371190T/pt unknown
- 2016-11-04 WO PCT/US2016/060468 patent/WO2017079519A1/en active Application Filing
- 2016-11-04 TW TW105136055A patent/TWI744256B/zh active
- 2016-11-04 AR ARP160103370A patent/AR106595A1/es unknown
- 2016-11-04 RS RS20220521A patent/RS63359B1/sr unknown
- 2016-11-04 HR HRP20220599TT patent/HRP20220599T1/hr unknown
- 2016-11-04 JP JP2018523015A patent/JP6854817B2/ja active Active
-
2018
- 2018-07-25 US US16/045,358 patent/US10472368B2/en active Active
-
2019
- 2019-10-01 US US16/589,523 patent/US11091491B2/en active Active
-
2021
- 2021-06-24 US US17/356,984 patent/US11773102B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11773102B2 (en) | 2023-10-03 |
SI3371190T1 (sl) | 2022-08-31 |
MA43169A (fr) | 2018-09-12 |
EP4086259A1 (en) | 2022-11-09 |
ES2915550T3 (es) | 2022-06-23 |
MA43169B1 (fr) | 2022-05-31 |
PT3371190T (pt) | 2022-07-08 |
EP3371190B1 (en) | 2022-03-30 |
US20190062336A1 (en) | 2019-02-28 |
HUE059324T2 (hu) | 2022-11-28 |
AR106595A1 (es) | 2018-01-31 |
US20230009843A1 (en) | 2023-01-12 |
US20200031837A1 (en) | 2020-01-30 |
LT3371190T (lt) | 2022-08-10 |
HRP20220599T1 (hr) | 2022-06-24 |
US10472368B2 (en) | 2019-11-12 |
US10065963B2 (en) | 2018-09-04 |
DK3371190T3 (da) | 2022-05-23 |
US20170129899A1 (en) | 2017-05-11 |
WO2017079519A1 (en) | 2017-05-11 |
EP3371190A1 (en) | 2018-09-12 |
MD3371190T2 (ro) | 2022-09-30 |
TW201726679A (zh) | 2017-08-01 |
TWI824309B (zh) | 2023-12-01 |
JP6854817B2 (ja) | 2021-04-07 |
US11091491B2 (en) | 2021-08-17 |
JP2018532760A (ja) | 2018-11-08 |
TW202204362A (zh) | 2022-02-01 |
PL3371190T3 (pl) | 2022-11-07 |
TWI744256B (zh) | 2021-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287267A (en) | The heterocyclic compounds as immunomodulators | |
HK1249905A1 (zh) | 作為lsd1抑制劑的雜環化合物 | |
HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
HK1258272A1 (zh) | 作為免疫調節劑的雜環化合物 | |
IL260166A (en) | Heterocyclic compounds as immunomodulators | |
PL3371190T3 (pl) | Związki heterocykliczne jako inhibitory pi3k-gamma | |
IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
IL254890B (en) | The tercyclic compound | |
GB201522245D0 (en) | Compounds useful as kinase inhibitors |